Pharmaceutical Executive May 11, 2022
With more promising products emerging, investment risks remain.
In late 2019, I interviewed Corey McCann, president and CEO of Pear Therapeutics, about his company, its products, and the digital therapeutics space. In September 2017, Pear’s lead product, reSET, for substance use disorder, was the first prescription digital therapeutic (PDT) granted FDA Class II medical device approval to treat disease. The company’s second product, reSET-O, for the treatment of opioid use disorder, received FDA marketing approval in December 2018. McCann said at the time, “We’ve gone effectively from zero understanding in 2015, 2016, to the point where this is a hot new modality in 2019.”
Keeping in mind that COVID-19 was just around the corner, developments in digital medicine and digital...
Today's Sponsors
Today's Sponsor